Teva Pharmaceutical Industries plans to use the DiaPep277 compound to develop a treatment that would replace insulin therapy in some patients with type 1 diabetes. In a trial, the drug appeared to promote stable C-peptide levels, an indication of insulin secretion by pancreatic cells, researchers said. The results of a second late-stage trial are expected in 2014.
Teva is developing compound for type 1 diabetes
SmartBrief Job Listings for Health Care
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|Catheter Engineer Manager||
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|
|Neurovascular Intervention Product Sales Rep, North East||
|Multiple Locations, SL_Multiple Locations|
|Senior Manager, Compliance||
|Director, Office of Device Evaluation||
FDA, Center for Devices and Radiological Health
|Silver Spring, MD|